Introducing breakthrough nanotechnology microneedle patch, designed to desensitise food allergies without the risk of oral exposure.
Food allergies like peanuts, eggs, and milk affect millions worldwide—often with life-threatening consequences. At Sallergen, we’ve pioneered a new approach: Epicutaneous Immunotherapy using a patented dissolving microneedle patch that delivers allergens through the skin, avoiding the risks associated with Oral Immunotherapy (OIT).
Developed after a decade of research at the University of New South Wales (UNSW) by Associate Professor Alice Lee. Our technology offers a smarter, safer alternative to oral immunotherapy. The patch’s microneedles painlessly breach the skin barrier, while our proprietary nanotechnology ensures ultra-precise dosing and controlled allergen delivery, minimising risk while maximising efficacy *.
Note: * clinical trials have not been completed.
Novel nanocarriers utilising peanut allergen-loaded liposomes are promising nanomaterials showing great potential as a vehicle for skin delivery in the context of EPIT.
Epicutaneous Immunotherapy or patch-based immunotherapy, has shown consistent evidence of efficacy, safety, and high treatment adherence in children with peanut allergy.
Increasing reactivity threshold in peanut-allergic children aged 4 to 11 years ... may also reduce the severity of allergic reactions to accidental peanut ingestion.
Two years of epicutaneous immunotherapy in young peanut-allergic children demonstrated continued increases in treatment effect without new safety signals.
My research aims to understand molecular allergology—how food components change during processing, interact with the gut immune system, and influence health, particularly in relation to food allergies.
If you have a food allergy or know someone who does, sign up now to register your interest and stay informed.
The next step involves completing a short profile questionnaire to help us assess and screen your eligibility.
If you meet the qualifying criteria after assessment, you'll be assigned to the most convenient clinical trial centre.
Interested in learning more about our product, or participating in a clinical trial:
Copyright ⓒ 2025 Immunogex Pty Ltd. T/A Sallergen (ABN 67 117 985 994)
